AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation

Stroke Main page
Patient Information
Overview
Causes
Classification Hemorrhagic stroke Ischemic stroke
Differentiating Stroke from other Diseases
Epidemiology and Demographics
Diagnosis NIH stroke scale Glasgow coma scale
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation
CDC on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation
AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation in the news
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for AHA/ASA guideline recommendations for prevention of stroke in women atrial fibrillation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]

2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)

Class I

"1. Risk stratification tools in atrial fibrillation that account for age and sex-specific differences in the incidence of stroke are recommended. (Level of Evidence: A) "

"2. Considering the increased prevalence of AF with age and the higher risk of stroke in elderly women with AF, active screening (in particular of women >75 years of age) in primary care settings using pulse taking followed by an ECG as appropriate is recommended. (Level of Evidence: B) "

"3. New oral anticoagulants are a useful alternative to warfarin for the prevention of stroke and systemic thromboembolism in women with paroxysmal or permanent AF and prespecified risk factors (according to CHA2DS2-VASc) who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance 15 mL/min), lower weight (<50 kg), or advanced liver disease (impaired baseline clotting function). (Level of Evidence: A) "

Class III (No Benefit)

" Oral anticoagulation in women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1) is not recommended. (Level of Evidence: B) "

Class IIa

" Antiplatelet therapy is a reasonable therapeutic option for selected low-risk women aged ≤65 years with AF alone (no other risk factors; women with CHADS2=0 or CHA2DS2-VASc=1). (Level of Evidence: B) "